Annexon Biosciences, Inc. (ANNX)
| Market Cap | 1.05B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 28.47M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $27.45 |
| Previous Close | $27.45 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 24.17 |
| Day's Range | 23.64 - 27.75 |
| Day's Volume | 138,828 |
| 52-Week Range | 17.50 - 30.55 |
News
There are no news available yet.
About ANNX
Annexon, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune and neurodegenerative diseases. It focuses on the treatment of body, brain, and eye disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, which has completed Phase 1b clinical trials to treat patients with guillain- barré syndrome; and ANX0... [Read more...]
| Industry Biotechnology | IPO Date Jul 24, 2020 |
| CEO Douglas Love J.D., Esq. | Employees 38 |
| Stock Exchange NASDAQ | Ticker Symbol ANNX |
Analyst Forecasts
According to 3 analysts, the average rating for ANNX stock is "Strong Buy." The 12-month stock price forecast is 34.50, which is an increase of 25.68% from the latest price.